Influence of Fibrinogen Degradation Products on Thrombin Time, Activated Partial Thromboplastin Time and Prothrombin Time of Canine PlasmaMischke R. · Wolling H.
Clinic for Small Animals, School of Veterinary Medicine, Hannover, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
To investigate how thrombin time, activated partial thromboplastin time (APTT) and prothrombin time are influenced by fibrinogen degradation products (FDP), different concentrations (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 and 1.0 mg/ml) of the purified FDP X, Y, D and E were added to the plasma of healthy dogs. If fragment Y was added to the plasma a considerable inhibitory effect could be demonstrated for all three test systems. A significant prolongation (p < 0.05) was found for concentrations of ≥0.1 mg/ml (thrombin time, APTT) and ≥0.2 mg/ml (prothrombin time). With FDP Y concentrations from >0.185 mg/ml (prothrombin time) to >0.24 mg/ml (APTT) coagulation time was prolonged beyond the respective reference range. As regards the other fragments, a comparable inhibitory effect could only be shown for fragment X added to the thrombin time test system. This effect can most probably be explained by the competition of the FDP X and fibrinogen for the fibrinogen binding sites of thrombin, rather than by a fibrin polymerization disorder. The results demonstrate that for plasma with normal fibrinogen concentration the group tests are only prolonged beyond the reference range at FDP concentrations very rarely found in spontaneous hyperfibrinolysis.
© 2000 S. Karger AG, Basel
- Feldman BF: Diagnostic approaches to coagulation and fibrinolytic disorders. Semin Vet Med Surg (Small Anim) 1992;7:315–322.
- Barth A, Furlan M, Lämmle B: Unerwartet verlängerte Thrombinzeit. Schweiz Med Wochenschr 1993;123:523–529.
Latallo ZS, Budzynski AZ, Lipinski B, Kowalski E: Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 1964;203:1184–1185.
Marder VJ, Shulman NR: High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem 1969;244:2110–2124.
- Larrieu MJ, Rigollot C, Marder VJ: Comparative effects of fibrinogen degradation fragments D and E on coagulation. Br J Haematol 1972;22:719–733.
- Wenzel E, Holzhüter H, Muschietti F Angelkort B, Ochs HG, Pusztai-Markes S, Nowak H, Stürmer H: Zuverlässigkeit des Fibrinogen-(Fibrin)-Spaltproduktnachweises im Plasma mit Thrombinkoagulase-, Reptilase- und Thrombingerinnungszeit. Dtsch Med Wochenschr 1974;99:746–756.
- Chen JP, Hutchison HAT, Nanninga LB, Mason Guest M: Characterization of the terminal degradation products of canine fibrinogen by plasmin. Biochim Biophys Acta 1975;386:69–79.
- Haverkate F, Timan G, Nieuwenhuizen W: Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 1979;9:253–255.
- Nieuwenhuizen W, Gravesen M: Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen, produced by plasmin (fragments X). Biochim Biophys Acta 1981;668:81–88.
- Nieuwenhuizen W, Voskuilen M, Hermans J: Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen (plasmin fragments Y). Biochim Biophys Acta 1982;708:313–316.
- Wolling H, Mischke R: Präparation und Reinigung von Milligramm-Mengen der caninen Fibrinogenspaltprodukte (FSP) -X, -Y, -D und -E. Berl Münch Tierärztl Wochenschr 1995;108:421–426.
Kazal LA, Amsel S, Miller OP, Tocantins LM: The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963;113:989–994.
- Heukoshoven J, Dernick R: Improved silver staining procedure for fast staining in Phast System development unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 1988;9:28–32.
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
Jacobsson K: Studies on fibrinogen. I. Studies on the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest 1955;7:1–54.
- Gaffney PJ: Fibrin(-ogen) interactions with plasmin. Haemostasis 1977;6:2–25.
- Marder VJ, Shulman NR: High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969;244:2111–2119.
- Wolling H, Mischke R: Einfluss von Calcium-Ionen auf die Spaltung von caninem und humanem Fibrin(ogen) durch (human-)Plasmin. Berl Münch Tierärztl Wochenschr 1995;108:373–379.
- Cooper HA, Bowie EJW, Owen CA: Evaluation of patients with increased fibrinolytic split products (FSP) in their serum. Mayo Clin Proc 1974;49:654–657.
- Sato N, Takahashi H, Shibata A: Fibrinogen/fibrin degradation products and D-dimer in clinical practice: Interpretation of discrepant results. Am J Hematol 1995;48:168–174.
- Hammer AS, Couto CG, Swardson C, Getzy D: Hemostatic abnormalities in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:11–14.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.